RECOMBINANT OF VV-GMCSF / LACT-DGF VIRUS OF OSVOVICINE, OF ONLY-COLIC ACTIVITY AND PRODUCING SECRETABLE CHIMERIC WHITE, CONTAINING FROM GRANULOCYTE-MACROPHAGAL COLONISTIMULATING HUMAN FACTOR AND ONCOTOXIC PROTEIN OF LACTAPTIN Russian patent published in 2017 - IPC C12N7/01 C12N15/27 C12N15/12 

FIELD: biotechnology.

SUBSTANCE: recombinant strain has targeted oncolytic activity and produces a secreted chimeric protein consisting of human GM-CSF and lactaptin (GMCSF/lact). The strain VV-GMCSF/lact-dGF is constructed on the basis of the L-IVP strain of the vaccinia virus, which contains deletions of fragments of viral thymidine kinase and growth factor genes. The transgene of the chimeric protein GMCSF/lact is incorporated into the deletion region of the thymidine kinase gene, which includes the GM-CSF gene adjuvant, which is linked through a flexible GlyGlyGlySer linker to the oncotoxic peptide lactaptin. The claimed strain has a virulence decreased by more than 100-fold as compared to the initial L-IVP strain, as well as a high targeted oncolytic activity against human tumor cells of various genesis. The strain was deposited in the State Collection of the causative agents of viral infections and rickettsiosis of the SSC VB Vector under the registration number V-711 (18.04.2016).

EFFECT: invention provides additional attenuation of the VACV virus against normal cells and enhances its lytic activity against cancer cells, and can also be used in biotechnology.

8 dwg, 3 tbl, 6 ex